AppliedVR
Cofounder and CEO Matthew Stoudt discusses AppliedVR's De Novo clearance from November, what's next for the company and the biggest trends from 2021.
The news comes about a week after AppliedVR announced it raised $36 million in Series B funding.
The Series B brings the company’s total raise to $71 million.
Also: NeuroFlow teams up with the Independence Blue Cross Foundation and Trinity Health Mid-Atlantic to provide its mental health software to frontline healthcare workers.
Also: Dexcare raises $20 million for healthcare management platform and Heard closes seed funding round.
In a recent study funded and coauthored by the company, the EaseVRx program outperformed a non-interactive headset app across several self-reported pain and pain-interference measures.
AppliedVR's EaseVRx landed an FDA Breakthrough Device designation for its tool that combines VR and cognitive behavioral therapy.
Also: Soterix Medical gets green light from FDA to trial its take-home transcranial direct-current stimulation therapy, while MammoScreen gets a 510(k).
At HIMSS last week, Samsung announced a partnership with Travelers Insurance, Cedars-Sinai Medical Center, Bayer, and AppliedVR around using virtual reality for pain management.